Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer
Open Access
- 30 March 2017
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (4) , 735
Abstract
Epigenetic alterations by promoter DNA hypermethylation and gene silencing in cancer have been reported over the past few decades. DNA hypermethylation has great potential to serve as a screening marker, a prognostic marker, and a therapeutic surveillance marker in cancer clinics. Some bodily fluids, such as stool or urine, were obtainable without any invasion to the body. Thus, such bodily fluids were suitable samples for high throughput cancer surveillance. Analyzing the methylation status of bodily fluids around the cancer tissue may, additionally, lead to the early detection of cancer, because several genes in cancer tissues are reported to be cancer-specifically hypermethylated. Recently, several studies that analyzed the methylation status of DNA in bodily fluids were conducted, and some of the results have potential for future development and further clinical use. In fact, a stool DNA test was approved by the U.S. Food and Drug Administration (FDA) for the screening of colorectal cancer. Another promising methylation marker has been identified in various bodily fluids for several cancers. We reviewed studies that analyzed DNA methylation in bodily fluids as a less-invasive cancer screening.Keywords
This publication has 115 references indexed in Scilit:
- Homeobox-Only Protein Expression Is a Critical Prognostic Indicator of Pancreatic Neuroendocrine Tumor and Is Regulated by Promoter DNA HypermethylationPancreas, 2016
- Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast CancerPLOS ONE, 2016
- Detection of Methylated CDO1 in Plasma of Colorectal Cancer; A PCR StudyPLOS ONE, 2014
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Epigenetic Silencing of HOPX Promotes Cancer Progression in Colorectal CancerNeoplasia, 2012
- Detection and quantification of mutations in the plasma of patients with colorectal tumorsProceedings of the National Academy of Sciences, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- About the possible origin and mechanism of circulating DNAClinica Chimica Acta, 2001
- Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.1999
- Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.1999